Evidence map›Paper›PMID 38581074›Full record

ArticleJournal of medical case reports2024

Patients' perspectives on buprenorphine subcutaneous implant: a case series.

Claudio Pierlorenzi, Marco Nunzi, Sabino Cirulli, Giovanni Francesco Maria Direnzo, Lucia Curatella, Sandra Liberatori, Annalisa Pascucci, Edoardo Petrone, Generoso Ventre, Concettina Varango and 6 more

Erratum issuedOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Claudio PierlorenziUOS Patologie da Dipendenza D9 ASL Roma 2, Rome, Italy.
Marco NunziUOS Patologie da Dipendenza D9 ASL Roma 2, Rome, Italy.
Sabino CirulliUOS Patologie da Dipendenza D9 ASL Roma 2, Rome, Italy.
Giovanni Francesco Maria DirenzoUOC Patologie da Dipendenza D8 ASL Roma 2, Rome, Italy.
Lucia CuratellaUOS Patologie da Dipendenza D9 ASL Roma 2, Rome, Italy.
Sandra LiberatoriUOC Patologie da Dipendenza D8 ASL Roma 2, Rome, Italy.
Annalisa PascucciUOC Patologie da Dipendenza D8 ASL Roma 2, Rome, Italy.
Edoardo PetroneUOS Terapia del Dolore ASL Roma 2 Ospedale S. Eugenio, Rome, Italy.
Generoso VentreUOC Patologie da Dipendenza D8 ASL Roma 2, Rome, Italy.
Concettina VarangoServizio Dipendenze Casalpusterlengo, ASST Lodi, Lodi, Italy.
Maria Luisa PulitoServizio Dipendenze Casalpusterlengo, ASST Lodi, Lodi, Italy.
Antonella VarangoServizio Dipendenze Casalpusterlengo, ASST Lodi, Lodi, Italy.
Cosimo DandoloServizio Dipendenze Casalpusterlengo, ASST Lodi, Lodi, Italy.
Brunella OccupatiTossicologia Medica, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Roberta MarenziASST Papa Giovanni XXII, Ospedale Di Bergamo, Bergamo, Italy.
Claudio LeonardiDipartimento Tutela Delle Fragilità ASL Roma 2, Rome, Italy. claudio.leonardi@aslroma2.it.
ASL Roma · ITOspedale Maggiore di Lodi · ITAzienda Ospedaliero-Universitaria Careggi · ITAzienda Sanitaria Locale Roma 3 · ITOspedale Papa Giovanni XXIII · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConsidering the enormous burden represented by the opioid use disorder (OUD), it is important to always consider, when implementing opioid agonist therapy (OAT), the potential impact on patient's adherence, quality of life, and detoxification. Thus, the purpose of the study is to evaluate how the introduction of a novel OAT approach influences these key factors in the management of OUD. CASE PRESENTATION: This article marks the pioneering use of OAT through buprenorphine implant in Europe and delves into the experience of six patients diagnosed with OUD at a relatively young age. The patients, comprising both males and a female, are of Caucasian Italian and African Italian ancestry (case 4) and exhibit an age range from 23 to 63, with an average drug abuse history of 19 ± 12 years. All patients were on stable traditional OAT before transitioning to buprenorphine implants. Despite the heterogeneity in social and educational backgrounds, health status, and drug abuse initiation histories, the case series reveals consistent positive treatment outcomes such as detoxification, absence of withdrawal symptoms and of side effects. Notably, all patients reported experiencing a newfound sense of freedom and improved quality of life.

conclusionsThese results emphasise the promising impact of OAT via buprenorphine implants in enhancing the well-being and quality of life in the context of OUD.

Indexed as

BuprenorphineOpioid-Related DisordersAdultAnalgesics, OpioidFemaleHumansMaleMiddle AgedOpiate Substitution TreatmentQuality of LifeYoung AdultAnalgesics, OpioidBuprenorphineBuprenorphine implantOpioid agonist therapyOpioid use disorderSublingual buprenorphine

Identifiers

PMID38581074
PMCPMC10998295
OpenAlexW4394742145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.